Bayer Aktiengesellschaft (BAYRY)
OTCMKTS
· Delayed Price · Currency is USD
6.74
-0.06 (-0.88%)
May 12, 2025, 3:59 PM EDT
Bayer Aktiengesellschaft Revenue
In the year 2024, Bayer Aktiengesellschaft had annual revenue of 46.61B EUR, down -2.16%. Bayer Aktiengesellschaft had revenue of 11.73B in the quarter ending December 31, 2024, a decrease of -1.12%.
Revenue
46.61B EUR
Revenue Growth
-2.16%
P/S Ratio
0.54
Revenue / Employee
514.49K EUR
Employees
90,587
Market Cap
26.28B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 46.61B | -1.03B | -2.16% |
Dec 31, 2023 | 47.64B | -3.10B | -6.11% |
Dec 31, 2022 | 50.74B | 6.66B | 15.10% |
Dec 31, 2021 | 44.08B | 2.68B | 6.48% |
Dec 31, 2020 | 41.40B | -2.15B | -4.93% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Bayer Aktiengesellschaft News
- 16 hours ago - Georgia’s governor is shielding Roundup weed killer’s maker from cancer warning lawsuits - Fortune
- 18 hours ago - Bayer to overhaul Crop Science division, cutting hundreds of jobs - Seeking Alpha
- 21 hours ago - Bayer to Slash Hundreds of Jobs in Crop Division Overhaul - WSJ
- 4 days ago - Bayer U.S. Surveys Shed Further Light on the Diversity of Menopause Care Approaches and Menopause Symptom Experiences - Business Wire
- 7 days ago - Don't Let Corn Rootworm Steal Your Yield: Bayer Launches The Watch 2025 - Business Wire
- 13 days ago - Plaintiffs' Attorneys Respond to Bayer's Threat to Pull Roundup from Market - Business Wire
- 14 days ago - Bayer Initiates Phase I Study Targeting GPC3 With Actinium-225 Radiopharmaceutical in Patients With Advanced Hepatocellular Carcinoma - Business Wire
- 14 days ago - Guru Ramamurthy Appointed as New CFO for Bayer's Crop Science Division - Business Wire